50.74
+3.87%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Septerna
From its filings with the US Securities and Exchange Commission
Septerna is based in South San Francisco, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker SEPN. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $46.0m and a net loss of $48.9m. At that date it held total assets of $596.2m and shareholders' equity of $381.9m.
We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (“GPCR”) oral small molecule drug discovery powered by our proprietary Native Complex Platform®. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.
GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body. Due to their significant role in human diseases, GPCRs have been the most productive target class in drug discovery history, accounting for approximately one-third of all FDA-approved drugs, representing approximately 500 products with combined global revenue of approximately $125 billion in 2023. Despite the pharmacological and commercial success of GPCR-targeted agents, about 75% of potential GPCR therapeutic targets remain undrugged. For certain validated GPCRs, novel binding pockets may exist that could offer enhanced therapeutic benefits. Each step in GPCR activation involves subtle conformational changes that have been historically challenging to reproduce outside of a cell.
Quoted from its 10-K, filed 9 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 25 Oct 2024
- Employees
- 130
- Website
- septerna.com ↗
- Head office
- 250 EAST GRAND AVENUE, SUITE 65, SOUTH SAN FRANCISCO, CA, 94080
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- <br>Emerging growth company
Leadership
Pay as last reported
- Dr. Jeffrey TongChairman of the Board, since 2019$129,316
- Ms. Elizabeth BhattPresident$1.6m
- Dr. Jeffrey FinerChief Executive Officer, Director, since 2019$4.7m
- Mr. Gil LabrucherieChief Financial Officer
- Ms. Samira ShaikhlyChief People Officer$742,536
- Dr. Uwe KleinSenior Vice President - Biological Sciences$578,530
- Mr. Daniel LongSenior Vice President - Drug Discovery$646,743
- Dr. Jae KimChief Medical Officer$1.9m
- Dr. Alan EzekowitzDirector$123,310
- Mr. Abraham BassanIndependent Director$125,620
- Dr. Bernard CoulieIndependent Director$181,904
- Dr. Keith GottesdienerIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Septerna Inc employs 130 staff members in the US pharmaceutical sector.
- The Native Complex Platform enables discovery of novel GPCR binding pockets.
- The pipeline targets endocrinology, immunology, and metabolic diseases with oral small molecules.
Weaknesses
- The company is a clinical-stage biotechnology firm with limited commercial history.
- Only 73 full-time employees are currently working at the South San Francisco headquarters.
- The firm relies on proprietary technology for its drug discovery programs.
Opportunities
- The IPO on 25 October 2024 provides capital for advancing GPCR programs.
- Targeting unmet needs in inflammation offers potential for significant therapeutic effects.
- Agonists and antagonists can achieve desired outcomes for validated receptors.
Threats
- Competitors in the Health Care sector may develop similar GPCR platforms.
- Regulatory hurdles for new oral small molecule drugs could delay approvals.
- Clinical trial failures in metabolic diseases might impact future revenue streams.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.